Skip to main content

Table 4 Transfusion requirements during the 48 hours after the first dose of trial drug in the placebo and rFVIIa groups

From: Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

  Placebo group rFVIIa group    
  n Median (range) n Median (range) Differences in medians Estimated reduction: median of differences (95% CI)a P valueb
RBC (units)        
   All patients 76 6.5 (0–41) 60 4.4 (0–39.9) 2.1 2.6 (0.1; 5.1) 0.02
   Alive at 48 hours 65 6.6 (0–41) 48 2.9 (0–20) 3.7 3.5 (1.7; 5.7) <0.001
FFP (ml)        
   All patients 60 1,360 (0–6,912) 42 705 (0–9,000) 655 600 (0.00; 1,320) 0.04
   Alive at 48 hours 54 1,400 (0–6,912) 35 660 (0–9,000) 740 800 (250.0; 1,420) 0.001
Platelets (ml)        
   All patients 72 300 (0–1,500) 55 147 (0–1,200) 153 50 (0; 250) 0.09
   Alive at 48 hours 62 300 (0–1,500) 46 100 (0–900) 200 50 (0; 250) 0.01
  1. aThe Hodges-Lehman shift with 95% CI. Patients who died within 48 hours were assigned the highest rank for the Wilcoxon-Mann-Whitney test and the Hodges-Lehman estimate. bTwo-sided Wilcoxon-Mann-Whitney rank sum test. CI, confidence interval; FFP, fresh frozen plasma; RBC, red blood cell; rFVIIa, recombinant activated factor VII.